Ipsen

1Exits tracked$800mDisclosed value$800mMedian price0Acquihires

Photo: Rhoda Baer (Photographer) / Wikimedia Commons, Public domain

Ipsen to buy Swiss biotech Memo Therapeutics for €200 million upfront plus milestones

The French drugmaker is paying for one asset: potravitug, a Phase II antibody against BK polyomavirus in kidney-transplant patients. Memo's discovery platform and other staff are being split off into a new company its shareholders keep.

Price$800mRaisedn/aLast stageSeries CBuyer typeCorporate

Latest in IpsenMore stories here soon.

All Ipsen exitsOpen tracker →

1 JulIpsen → Memo TherapeuticsSchlieren · Series C · raised n/a$800m$250m–1bn